IMMUNITYBIO INC (IBRX)
US45256X1037 - Common Stock
ChartMill assigns a Buy % Consensus number of 83% to IBRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.65. This target is 0% below the current price.
IBRX was analyzed by 8 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about IBRX.
In the last month the buy percentage rose by 40 points. So the trust of analysts is improving.
IBRX was analyzed by 8 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-04-29 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2024-03-25 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2023-05-12 | Piper Sandler | Downgrade | Overweight -> Neutral |
| 2022-08-03 | Jefferies | Initiate | Buy |